Adamis Pharmaceuticals reported -10354620 in Net Income for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Adma Biologics ADMA:US $ -25.01M 8.36M
Brainstorm Cell Therapeutics BCLI:US $ -5.36M 0.83M
Cara Therapeutics CARA:US $ -27749000 5.63M
Cerulean Pharma CERU:US $ -8.4M 1.14M
GlaxoSmithKline GSK:LN 1802M 1053M
Glaxosmithkline GSK:US $ 1802M 1053M
Merk MRK:US $ 4310M 552M
Pfizer PFE:US $ 7863M 4470M